ENDRA Life Sciences (NASDAQ:NDRA) Shares Up 2% – Here’s Why

ENDRA Life Sciences Inc. (NASDAQ:NDRA)’s stock price rose 2% during mid-day trading on Friday . The company traded as high as $5.39 and last traded at $4.9680. Approximately 10,633 shares traded hands during trading, a decline of 46% from the average daily volume of 19,670 shares. The stock had previously closed at $4.87.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of ENDRA Life Sciences in a research report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $30.00.

ENDRA Life Sciences Stock Performance

The firm has a market capitalization of $6.16 million, a P/E ratio of -0.56 and a beta of -0.11. The stock has a fifty day moving average price of $4.33 and a two-hundred day moving average price of $4.82.

Institutional Investors Weigh In On ENDRA Life Sciences

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new stake in ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the fourth quarter, according to its most recent filing with the SEC. The fund purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences comprises 0.9% of Altium Capital Management LLC’s portfolio, making the stock its 17th biggest position. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences as of its most recent filing with the SEC. 1.19% of the stock is currently owned by institutional investors and hedge funds.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.